A retrospective study published in the European Journal of Cancer this month looked at the activity of cabozantinib after immune checkpoint inhibitors in people with metastatic clear cell renal cell carcinoma (RCC).

The overall response rate was 36%, with a median overall survival of 13 months. Cabozantinib appeared to be well tolerated and there were no new side effects reported.

In conclusion, cabozantinib could be used after immune checkpoint inhibitors for the treatment of metastatic RCC.

Read more in the European Journal of Cancer here